Skip to main content
Premium Trial:

Request an Annual Quote

Santaris to Present Phase IIa Data on HCV Drug

Premium

This story has been updated to correct the date of Santaris' presentation.

Santaris Pharma announced this week that it will present final phase IIa data on its microRNA-targeting hepatitis C therapy miravirsen at the European Association for the Study of the Liver annual meeting this month.

“The data show that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent antiviral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA that was sustained well beyond four weeks beyond the end of therapy,” the company said.

Santaris reported earlier this year that it is aiming for a second phase II trial to study the miR-122-targeting drug in combination with a direct-acting antiviral agent (GSN 1/12/2012).

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.